Dexmedetomidine post-treatment exacerbates metabolic disturbances in septic cardiomyopathy via α2A-adrenoceptor.

MLA

Xu, Yaqian, et al. “Dexmedetomidine Post-Treatment Exacerbates Metabolic Disturbances in Septic Cardiomyopathy via Α2A-Adrenoceptor.” Biomedicine & Pharmacotherapy, vol. 170, Jan. 2024, p. N.PAG. EBSCOhost, https://doi.org/10.1016/j.biopha.2023.115993.

APA

Xu, Y., Zhang, X., Tang, X., Zhang, C., Cahoon, J. G., Wang, Y., Li, H., Lv, X., Wang, Y., Wang, Z., Wang, H., & Yang, D. (2024). Dexmedetomidine post-treatment exacerbates metabolic disturbances in septic cardiomyopathy via α2A-adrenoceptor. Biomedicine & Pharmacotherapy, 170, N.PAG. https://doi.org/10.1016/j.biopha.2023.115993

Chicago

Xu, Yaqian, Xue Zhang, Xiangxu Tang, Chanjuan Zhang, Jason G. Cahoon, Yingwei Wang, Hongmei Li, et al. 2024. “Dexmedetomidine Post-Treatment Exacerbates Metabolic Disturbances in Septic Cardiomyopathy via Α2A-Adrenoceptor.” Biomedicine & Pharmacotherapy 170 (January): N.PAG. doi:10.1016/j.biopha.2023.115993.